Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Toxicant Induced Chronic Multisymptom Illness and Associated Symptoms and Comorbidities

In brief

This research study is being conducted to see if coenzyme Q10 (a nutritional supplement) might help to prevent and/or alleviate symptoms and health consequences and help to improve quality of life and physical function in residents affected by the February 2023 East Palestine, Ohio train derailment. This is a pilot study that is not powered to achieve benefit but seek to examine effect size and variance to aid in power calculations for a potential future better powered study.

Key facts

Study ID

NCT06962657

Run by

University of California, San Diego

People needed

20

Starts

2026-05-15

Expected to finish

2028-10-01

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• On Feb. 3, 2023, lived within 10 miles of the East Palestine, OH train derailment (closer in will receive preference). Others who were in the area for toxin mitigation and other reasons and show compatible symptoms will also be eligible.
• Meets Kansas symptom criteria for multi-symptom illness - originally defined for Gulf War Illness (has persistent symptoms, lasting greater than six months, that are of >mild severity in at least three of the six domains of fatigue/sleep, pain, neurological/cognitive/mood, gastrointestinal, respiratory and dermatologic). At least some symptoms must be new or worsened since the derailment.
• Access to internet and smart phone or computer for remote Qualtrics survey participation.
• Willing to perform the stipulated study elements.
• Took ≥80% of run-in soft gels.

You may not qualify if…

• Anticipated move from the area or other anticipated obstacle to participating for study duration.
• Participating in another clinical trial.
• Has a pre-existing health condition expected to produce significant and variable fluctuating symptoms (e.g. chronic infection and/or active cancer other than non-melanoma skin cancer).
• Contraindications to CoQ10, such as use of coumadin (although an interaction with CoQ10 is controversial).

Where it is running

• UC San Diego — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.